Section one: Contracting authority/entity
one.1) Name and addresses
Ministry of Defence
Bristol
Country
United Kingdom
NUTS code
UK - United Kingdom
Internet address(es)
Main address
one.4) Type of the contracting authority
Ministry or any other national or federal authority
one.5) Main activity
Defence
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)
two.1.2) Main CPV code
- 33651520 - Immunoglobulins
two.1.3) Type of contract
Supplies
two.1.4) Short description
The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), intends to place a contract with Emergent Biosolutions Canada Inc for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 10 years (5 + 5 Option Years) with an estimated value of £20m. This is necessary to ensure maintenance of the capability with an acceptable stockholding level.
two.1.6) Information about lots
This contract is divided into lots: No
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £22,000,000
two.2) Description
two.2.3) Place of performance
NUTS codes
- CA - Canada
two.2.4) Description of the procurement
The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), intends to place a contract with Emergent for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 10 years (5 + 5 Option Years) with an estimated value of £20M+. This is necessary to ensure maintenance of the capability with an acceptable stockholding level.
Due to the estimated contract value and on the basis that it is to be placed directly with Emergent Biosolutions Canada Inc, the contract will be a Qualifying Defence Contract (QDC) and shall comply with the Single Source Contract Regulations (SSCR) 2014. It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where “Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons”.
Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT®) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence.
two.2.5) Award criteria
Price
two.2.11) Information about options
Options: Yes
Description of options
5 Optional Years
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2.14) Additional information
Due to the limitations of the character limit at II 2.4) Description — it is not possible to enter the full details of the single source justification, for full details of the reasoning, please email Tamika.Kelly116@mod.gov.uk so that it can be forwarded to you.
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Negotiated procedure without publication of a contract notice
- No tenders or no suitable tenders/requests to participate in response to negotiated procedure with prior publication of a contract notice
- The products involved are manufactured purely for the purpose of research, experiment, study or development
- The works, supplies or services can be provided only by a particular economic operator for the following reason:
- absence of competition for technical reasons
Explanation:
It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where “Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons”. Summary of the Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT®) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence.
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: No
Section five. Award of contract/concession
Contract No
CBRN/00272
Title
SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)
A contract/lot is awarded: Yes
five.2) Award of contract/concession
five.2.1) Date of conclusion of the contract
7 June 2022
five.2.2) Information about tenders
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor/concessionaire
Emergent Biosolutions Canada Inc
Winnipeg
Country
Canada
NUTS code
- CA - Canada
The contractor/concessionaire is an SME
No
five.2.4) Information on value of contract/lot/concession (excluding VAT)
Total value of the contract/lot/concession: £22,000,000
five.2.5) Information about subcontracting
The contract/lot/concession is likely to be subcontracted
Section six. Complementary information
six.4) Procedures for review
six.4.1) Review body
Ministry of Defence
Bristol
Country
United Kingdom